Longduoduo Co Ltd (LDDD) stock
Close on Oct 16, 2026Market cap $15.31MP/E –Yield –
Longduoduo Co Ltd saw revenue fall 57.2% to $1.82M over the twelve months to Jun 30, 2026. Operating income fell 214.6% to -$633.18K, moving the operating margin from 13.0% to -34.7%. Free cash flow was -$193.75K, down 188.9% from a year earlier. At the latest close the market valued the company at $15.31M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $15.31M
- P/E ratio
- –
- Price to sales
- 8.40
- Price to book
- 21.75
- Dividend yield
- –
- Free cash flow yield
- -1.27%
Fundamentals
- Revenue
- $1.82M
- Net income
- -$578.63K
- EPS, diluted
- -$0.02
- Free cash flow
- -$193.75K
- Book value per share
- $0.02
- Diluted shares
- 30M
Trading
- Previous close
- $0.51
- Open
- $0.51
- Day's range
- $0.51 – $0.51
- Volume
- 0
Market cap history
Month-end market cap since 2023, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 16, 2026. The S&P 500 is measured by the SPY fund.
| Period | LDDD | S&P 500 | Difference | LDDD per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | 0.0% | +1.5% | −1.5 pts | ||
| 3 months | 0.0% | +1.9% | −1.9 pts | ||
| Year to date | -14.0% | +12.8% | −26.8 pts | ||
| 1 year | -45.4% | +16.8% | −62.2 pts | ||
| 3 years | -91.2% | +81.5% | −172.7 pts | -55.5% | +22.0% |
Six years at a glance
Fiscal years 2021 to 2026, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
About Longduoduo
Services-Health Services
Longduoduo Company Limited operates as a sales agent and distributor of third-party preventive healthcare services and products. Through its operating subsidiaries, the company markets preventive healthcare solutions, including immunological ozonated autohemotherapy, double blood purification, meridian-regulating and consciousness-restoring treatments, and gut health testing and products. These offerings primarily focus on preventing cardiovascular and cerebrovascular conditions as well as gastrointestinal disorders. The business functions through two primary models: commissioned agency sales, where it promotes services developed and delivered by an external health management partner, and principal sales, where it purchases and resells medical and wellness services directly from licensed third-party clinics and hospitals. Its customers consist of individuals seeking disease screening and health maintenance.
Company profile, executives and historyLongduoduo stock: common questions
What is Longduoduo's stock price?
LDDD closed at $0.51 on Oct 16, 2026, up 0.00% on the day.
What is Longduoduo's market cap?
Longduoduo was worth $15.31M at the close on Oct 16, 2026: the share price times the diluted shares outstanding.
What is LDDD's P/E ratio?
Longduoduo lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.02), so it has no meaningful P/E ratio.
How much revenue does Longduoduo make?
Longduoduo reported revenue of $1.82M for the twelve months to Jun 30, 2026, down 57.2% from a year earlier.
Does Longduoduo pay a dividend?
No. Longduoduo has not paid a cash dividend over the last twelve months.
How has LDDD stock performed over the past year?
Including dividends, LDDD returned -45.4% over the past year, against +16.8% for the S&P 500.
Who are Longduoduo's competitors?
Companies most similar to Longduoduo by business, industry and size include ATPC, EUDA, ALPS, AAQL, MCTA.
See a number that looks wrong?